The pandemic caused by the SARS-CoV2 virus has prompted research into new therapeutic solutions that can be used to treat the CoVid-19 syndrome. As part of this research, immunotherapy, first developed against cancer, is offering new therapeutic horizons also against viral infections. CAR technology, with the production of CAR-T cells (adoptive immunotherapy), has shown applicability in the field of HIV viral infections through second generation CAR-T cells implemented with the "CD4CAR" system with a viral fusion inhibitor. In addition, to avoid the immunoescape of the virus, bi- or trispecific CAR receptors have been developed. Our research group hypothesizes the use of this immunotherapy system against SARS-CoV2, admitting the appropriate adjustments concerning the target-epitope and a possible remodeling of the nuclease related to the action of this virus. For a more in-depth analysis of this hypothesis, a mathematical model has been developed which, starting from the fractional derivative Caputo, creates a system of equations that describes the interactions between CAR-T cells, memory cells, and cells infected with SARS-CoV2. Through an analysis of the existence and non-negativity of the solutions, the hypothesis is stabilized; then is further demonstrated through the use of the piece-wise derivative and the consequent application of the formula of Newton polynomial interpolation.
Keywords: CAR-T cells; Dynamical analysis; Piecewise approach; SARS-2.
© 2021 The Author(s).